The drug was discovered by Incyte, for the treatment of adult patients with myelofibrosis, a bone marrow disease. The drug has moved Incyte, which is based at the DuPont Experimental Station into the profit column.
Incyte entered into a worldwide collaboration and license agreement with Novartis in 2009. Novartis received exclusive rights to the development and potential commercialization outside of the United States. Incyte retained exclusive rights for the development and commercialization of ruxolitinib in the United States, and received approval from the U.S. Food and Drug Administration in November 2011 for ruxolitinib, marketed in the United States under the brand name Jakafi.